Efficacy of Empagliflozin as a Novel Therapeutic Agent for Hypertension: A Systematic Review
Abstract
Results: Of 314 studies screened, 4 RCTs with 1598 patients met inclusion criteria. Empagliflozin 10 mg and 25 mg demonstrated significant reductions in mean 24-hour systolic and diastolic blood pressure, with the 25 mg dose showing a stronger effect. Dapagliflozin 10 mg also significantly reduced seated systolic blood pressure compared to placebo. Meta-analysis showed pooled reductions in systolic blood pressure (SBP: -4.27 mmHg; 95% CI: -5.11 to -3.43, P < 0.00001) and diastolic blood pressure (DBP: -3.83 mmHg; 95% CI: -4.10 to -3.57, P < 0.00001), favoring SGLT-2 inhibitors. Conclusion: SGLT-2 inhibitors provide clinically meaningful blood pressure reductions in hypertensive T2DM patients, with empagliflozin 25 mg and dapa-gliflozin 10 mg being particularly effective.
How strong is the evidence?
Evidence Hub reads this as a systematic review. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,598 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.